BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36373485)

  • 1. Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort.
    Zhu L; Mao N; Yi C; Simayi A; Feng J; Feng Y; He M; Ding S; Wang Y; Wang Y; Wei M; Hong J; Li C; Tian H; Zhou L; Peng J; Zhang S; Song C; Jin H; Zhu F; Xu W; Zhao J; Bao C
    Emerg Microbes Infect; 2023 Dec; 12(1):2146535. PubMed ID: 36373485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection.
    Simayi A; Li C; Chen C; Wang Y; Dong C; Tian H; Kong X; Zhou L; Peng J; Zhang S; Zhu F; Hu J; Xu K; Jin H; Fan H; Bao C; Zhu L
    Front Immunol; 2023; 14():1083523. PubMed ID: 36761738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections.
    Brazer N; Morris MK; Servellita V; Anglin K; Saldhi P; Garcia-Knight M; Bethancourt S; Sotomayor-Gonzalez A; Wang B; Foresythe A; Nguyen J; Gliwa AS; Pineda-Ramirez J; Sanchez RD; Zhang Y; Ott M; Wadford DA; Andino R; Kelly JD; Hanson C; Chiu CY
    J Infect Dis; 2022 Nov; 226(10):1688-1698. PubMed ID: 36134603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
    Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
    Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.
    Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
    Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
    Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
    Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
    Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
    Li J; Li J; Dai S; Dang L; Wang L; Cao L; Chen X; Wang Y; Ge M; Liu W; Song Q; Xu W; Ma L
    Front Immunol; 2023; 14():1269665. PubMed ID: 37828994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China.
    Zhang H; Hua Q; Nani Xu N; Zhang X; Chen B; Ma X; Hu J; Chen Z; Yu P; Lei H; Wang S; Ding L; Fu J; Liao Y; Yang J; Jiang J; Lv H
    Elife; 2023 Mar; 12():. PubMed ID: 36928099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
    Planas D; Staropoli I; Porot F; Guivel-Benhassine F; Handala L; Prot M; Bolland WH; Puech J; Péré H; Veyer D; Sève A; Simon-Lorière E; Bruel T; Prazuck T; Stefic K; Hocqueloux L; Schwartz O
    Med; 2022 Dec; 3(12):838-847.e3. PubMed ID: 36228619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants.
    Hirabidian M; Bocket L; Demaret J; Vuotto F; Rabat A; Faure K; Labalette M; Hober D; Lefevre G; Alidjinou EK
    J Clin Virol; 2022 Oct; 155():105268. PubMed ID: 35998394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay.
    Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S
    Front Immunol; 2022; 13():1039163. PubMed ID: 36505453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Li J; Gong L; Li J; Gong Z; Wang X; Yan H; Zhang Y; Mao H; Chen K
    Vaccine; 2024 Jul; 42(18):3751-3755. PubMed ID: 38714449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.